Avidity Biosciences Inc. (RNA) News

Avidity Biosciences Inc. (RNA): $16.33

-0.39 (-2.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 385

in industry

Filter RNA News Items

RNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RNA News Highlights

  • For RNA, its 30 day story count is now at 11.
  • Over the past 28 days, the trend for RNA's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • DRUG, XFOR and MYO are the most mentioned tickers in articles about RNA.

Latest RNA News From Around the Web

Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.

Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the Phase 1/2 FORTITUDE™ clinical trial of AOC 1020 in adults with facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare, hereditary muscle-weakening condition marked by life-long, progressive loss of muscle function and causes significant pain, fatigue, and disability. AOC 1020 is the second muscl

Yahoo | September 29, 2022

Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study

Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.

Yahoo | September 28, 2022

Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (XFOR) and Avidity Biosciences (RNA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and Avidity Biosciences (RNA – Research Report) with bullish sentiments. X4 Pharmaceuticals (XFOR) In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on X4 Pharmaceuticals, with a price target of $6.50. The company's shares closed last Tuesday at $1.04, close to its 52-week low of $0.86. According to TipRanks.

Christine Brown on TipRanks | September 27, 2022

Avidity (NASDAQ: RNA) Tanks After FDA Places Partial Hold on Clinical Trial

kg cohort of the MARINA study.

Shrilekha Pethe on TipRanks | September 27, 2022

Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study

The FDA placed a myotonic dystrophy study from Avidity Biosciences on partial hold Tuesday, leading RNA stock to collapse.

Yahoo | September 27, 2022

FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial

The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). DM1 is a type of muscular dystrophy, a group of genetic disorders that cause progressive muscle loss and weakness. Close to 40 participants have currently enrolled in the MARINA and MARINA open-label extension (MARINA-OLE) trials. The partial clinical hold is in response to a serious adverse event re

Yahoo | September 27, 2022

Avidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trial

Shares of Avidity Biosciences Inc. tumbled 23.7% in premarket trading on Tuesday after the company said the Food and Drug Administration placed a partial clinical hold on new enrollment in a Phase 1/2 clinical trial trial evaluating a new treatment for myotonic dystrophy type 1, a progressive neuromuscular disease. Avidity said the partial hold is the result of a serious adverse event reported in one patient. The adverse event "driving the partial hold is currently undisclosed, but we think it i

Yahoo | September 27, 2022

Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Close to 40 participants are currently enrolled in the MARINA and MARINA open label extension

Yahoo | September 27, 2022

7 Unknown Biotech Stocks That Could Rocket in 2023

Unknown biotech stocks that are poised for a big rally in 2023.

Faisal Humayun on InvestorPlace | September 23, 2022

Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases. This month Avidity will also raise awareness and support patient-focused activities for World Duchenne Awareness Day on September 7 and International Myo

Yahoo | September 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5535 seconds.